Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDNF Infusion for Progressive Supranuclear Palsy
NCT00005903Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Jun 2000
- Modality
- Gene Editing, Gene Silencing, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of glial cell line-derived neurotrophic factor in progressive supranuclear palsy (PSP), sponsored by National Institute of Neurological Disorders and Stroke. Started Jun 2000; status: completed.
02
Drugs
glial cell line-derived neurotrophic factor
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT00005903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005903.